NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges
Neuropace's Financial Health: Navigating Risks Tied to RNS System Dominance and Supplier Dependencies
NeuroPace's Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to
Express News | Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
NeuroPace Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 95.41% Cantor Fitzgerald → $18 Reiterates Overweight → Overweight 03/14/2024 117.12% Wells Farg
Q1 2024 Neuropace Inc Earnings Call
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), NeuroPace (NPCE) and Dynavax (DVAX)
NeuroPace Maintains FY24 Revenue Guidance Of $73M-$77M, Est $75.205M
Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including approximately $12 million in stock-based compensation, a noncash expense.The
NeuroPace | 10-Q: Quarterly report
NeuroPace Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $18.124M Beat $17.302M Estimate
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 21.95 percent increase over losses of $(0.41) per
Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, Vs. Street Est of $17.3M
04:15 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M
Express News | Neuropace Reports First Quarter 2024 Financial Results and Provides Corporate Update
Express News | Neuropace, Inc. Q1 Gross Profit USD 13.343 Million
Express News | Neuropace, Inc. Outlook FY Revenue USD 73-77 Million
Express News | Neuropace, Inc. Q1 Income From Operations USD -7.545 Million Vs. Ibes Estimate USD -7.55 Million
Express News | Neuropace, Inc. Q1 EPS USD -0.32 Vs. Ibes Estimate USD -0.32
Express News | Neuropace, Inc. Outlook FY Gross Margin 72-74%
Express News | Neuropace, Inc. Q1 Operating Expenses USD 20.888 Million
Express News | Neuropace, Inc. Q1 Revenue USD 18.124 Million Vs. Ibes Estimate USD 17.3 Million
No Data